HRS-7058 clinical trials
Also written HRS-7058.
How each study uses HRS-7058 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-7058 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HRS-7058
- 4
Studies by the year they started
6 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Shandong Suncadia Medicine Co., Ltd. (4) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · Fudan University (1)
Often tested with
Tested in the same studies.
Adebrelimab (2) · SHR-1826 (2) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (2) · SHR-1701 (1) · Xelox (1) · KRAS G12D Inhibitor HRS-4642 (1) · BP102 (1) · Bevacizumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test HRS-7058.
- Dec 2026A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant TumourPhase 2 · Shandong Suncadia Medicine Co., Ltd.
- Jun 2027A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid TumorsPhase 2 · Shandong Suncadia Medicine Co., Ltd.
Studies
Open first, then newest update. How each study uses HRS-7058 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung CancerNot yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07704645Written as Adebrelimab Injection combined with HRS-7058 Capsule
- An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic CancerRecruitingPhase 2Shandong Suncadia Medicine Co., Ltd.NCT07589569Written as HRS-7058
- A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard TreatmentNot yet recruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07601048Written as HRS-7058
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07503639Written as HRS-7058
- A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid TumorsRecruitingPhase 2Shandong Suncadia Medicine Co., Ltd.NCT07032077Written as HRS-7058
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant TumourRecruitingPhase 2Shandong Suncadia Medicine Co., Ltd.NCT06915142Written as HRS-7058 + SHR-1316